Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...